中国临床药理学与治疗学2025，Vol.30Issue(8)：1084-1091,8.DOI:10.12092/j.issn.1009-2501.2025.08.009
利拉鲁肽治疗后2型糖尿病合并冠心病患者肠道菌群变化及其与糖、脂代谢指标相关性
Changes of intestinal flora in patients with type 2 diabetes mellitus complicated with coronary heart disease after liraglutide treatment and its correlation with glucose and lipid metabolism indexes
摘要
Abstract
AIM:To explore the changes of intesti-nal flora in patients with type 2 diabetes mellitus complicated with coronary heart disease after lira-glutide treatment and its correlation with glucose and lipid metabolism indexes.METHODS:Twenty-six patients with type 2 diabetes mellitus complicat-ed with coronary heart disease were selected to compare the changes of glucose and lipid metabo-lism indexes and intestinal flora(high-throughput sequencing technique)before and after liraglutide treatment,and to analyze the correlation between glucose and lipid metabolism indexes and intestinal flora.RESULTS:Compared with those before treat-ment,the indexes of glucose metabolism and lipid metabolism in the patients were significantly de-creased(P＜0.01).Liraglutide had no significant ef-fect on the diversity of intestinal flora(P＞0.05),but can significantly change the composition of intesti-nal flora(P＜0.05).While beneficial bacteria such as Lachnospiraceae increased significantly,it signifi-cantly reduced the abundance of pathogenic bacte-ria such as Escherichia_Shigella(P＜0.05),and pro-moted the production of short-chain fatty acids and body metabolism.CONCLUSION:Lilalutide can affect the composition of intestinal flora in type 2 diabetes patients with coronary heart disease,and then participate in the regulation of glucose and lipid metabolism.关键词
2型糖尿病/冠心病/肠道菌群/利拉鲁肽Key words
type 2 diabetes/coronary heart dis-ease/intestinal flora/liraglutide分类
医药卫生引用本文复制引用
邢英,郑嵘炅,姜春晖,玛依拉·卡哈尔,木胡牙提·乌拉斯汉..利拉鲁肽治疗后2型糖尿病合并冠心病患者肠道菌群变化及其与糖、脂代谢指标相关性[J].中国临床药理学与治疗学,2025,30(8):1084-1091,8.基金项目
2025年度自治区卫生健康保健科研专项项目(BL202518) （BL202518）
